Sentences with phrase «of drug prices»

Sanofi's CEO On The New York Times» Criticism Of Drug Prices And Surviving The Patent Cliff — Forbes

It issued six recommendations to ensure alignment of drug prices with their value, promote use of high - value drugs, and support innovation in cancer drug development.

Infuriating members of Congress, a smirking Martin Shkreli took the Fifth at a Capitol Hill hearing Thursday when asked about his jacking up of drug prices, then promptly went on Twitter and insulted his questioners as «imbeciles.»

Federal investigators are also said to be looking at the issue of drug prices, and several companies, including Valeant Pharmaceuticals International, have said they have received subpoenas.

Meanwhile, rapid escalation of drug prices continues unabated.

And within a span of six weeks this fall, Hillary Clinton caused a drop in biotech stocks with a tweet calling for greater regulation of drug prices, then single - handedly tanked stocks of private - corrections companies when she tweeted about prison reform.

The same outside adviser, who was unidentified in Tuesday's release, advised that a package of assistance programs to patients would: «force reporters to focus on the byzantine nature of drug pricing and health care and ensure the patient message gets out... specifically tie profits from Daraprim to the research and development of a new and more effective treatment for Daraprim patients.

Lawmakers and regulators (and presidential hopefuls) have been ramping up their scrutiny of drug pricing practices amid several flagrant instances of alleged price gouging (see Turing Pharmaceuticalsand Valeant), and consumer advocates are becoming more vocal about the price of even generic pharmaceuticals.

It will be interesting to see how Witty takes on this new role on the opposite end of the drug price war.

There is, of course, a never - ending debate about the ethics of drug pricing.

This is a hefty price tag yet may be necessary to compete in the increasingly competitive healthcare space in the face of drug pricing pressures.

Fujian Drug Price Reform Letter: Letter seeking delayed implementation of drug price reform pilot Read the full comment letter...

Theoretically, better regulation of drugs pricing might increase the cost efficiency of the health system, without changing other aspects.

He pointed out, too, that the rate of drug price hikes has been declining in recent quarters — an indication, he said, that even without political action, «the pricing environment today is already dramatically different from what it was in 2013 to 2015.»

Although many have questioned the ethics of that profit and the burden of the drug price on the health - care system, Beall says that without Vertex, there would be no drug.

JL: As I was trying to run through modern day boogie men, I kept coming back to Martin Shkreli [the guy convicted of drug price gauging].

Not exact matches

Sidenote: Chew is also one of the few biopharma execs I've ever spoken to who voluntarily brought up the Institute for Clinical and Economic Review (ICER), a tough drug pricing critic organization which insists on proven outcomes (and has consequently become a major biopharma gadfly), because the group actually validated the cost - effectiveness of Omada's tech.

A new study published in the New England Journal of Medicine finds that Valeant Pharmaceuticals» infamous price hikes for a pair of heart drugs called nitroprusside and isoproterenol — whose prices were increased by 310 % and 720 %, respectively — had significant downstream effects on patient care.

By contrast, while the cost of older, branded pharmaceuticals continue to rise and contribute to increased spending, when discounting is considered, prices of these drugs increased, on average, 2.8 % in 2015, the lowest growth rate in years.

Roughly 80 % of the spending growth on these patent - protected drugs was offset by rebates and price concessions.

That trajectory that will surprise no one who follows the news, or the bipartisan campaign - season bashing of the nation's sky - high prescription drug prices.

May 1 - Regeneron Pharmaceuticals and Sanofi will cut the net price of their expensive cholesterol drug for Express Scripts customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.

But sales of Praluent and a rival Amgen drug, with list prices of more than $ 14,000 a year before discounts, have been severely constrained by onerous roadblocks to patient access by insurers.

However... «if Amazon were successful in changing the brand pricing model to be based on «net» price versus the current gross model, we estimate a portion of rebates and other supply chain discounts currently being retained by plan sponsors, PBMs, and to a lesser degree drug distributors could pass back to consumers.»

But sales of Praluent and a rival Amgen drug, with list prices of more than $ 14,000 a year before discounts, have...

But sales of Praluent and a rival Amgen drug, with list prices of more than $ 14,000 a year before discounts, have been constrained by onerous roadblocks to patient access by insurers.

«What this shows is that increased competition among manufacturers, the aggressive negotiations by pharmacy benefits managers, and to some extent the significant public discussion about drug pricing and prices have all contributed to a relatively modest level of growth in 2015,» says Murray Aitken, Executive Director of the IMS Institute.

House Democrats push for explanation of high MS drug prices.

The drug at the heart of four lawsuits in New Jersey is insulin — «a century - old medicine that for most of its history cost $ 15 or less,» write Barrett and Langreth, but «whose list price has risen more than 270 percent over the past decade.»

«If your drug prices aren't flat or going down every year, I know who's getting the money, and it should not be happening,» says Craig Burridge, the recently retired executive director of the New York State Pharmacists Society.

But the real issue on pricing is the year - on - year rises on old drugs — the deflection is to talk about new drug prices, but the sleight of hand is on the double digit rises taken every year on the portfolio staples.

A 2012 report by the Kaiser Family Foundation calls the PBM assertions of Medicare savings «overstated» and says the reduced cost probably stemmed from incorrectly high predictions of prices and from brand drugs going generic.

Miller, chief investment officer at LMM, said he thinks the embattled drugmaker is «a completely different company» than the one that was under severe fire for jacking up drug prices, and could see returns of 25 percent to 30 percent per year over the next five years.

He first gained notoriety back in September, after raising the price of a life - saving AIDS drug from $ 13.50 to $ 750 a pill.

Mark Merritt, CEO of the Pharmaceutical Care Management Association (PCMA), a trade group representing the 10 largest traditional PBMs, says that while «drug prices have gone up more than we'd like» over the years, his members have saved employers 25 %.

Soliris's price can run as high as $ 700,000 a year, with the drug accounting for the bulk of Alexion's $ 3 billion in 2016 sales.

Swiss drug giant Novartis has struck a deal to acquire France's Advanced Accelerator Applications (AAA) for $ 3.9 billion, or a nearly 50 % premium on the company's closing share price before knowledge of the deal became public.

And, as Barrett and Langreth write, drug makers often raise those list prices «to make up some of the lost revenue» from rebating.

The investigation targets Valeant Pharmaceuticals and Turing Pharmaceuticals, two of the biggest offenders of price hikes on older drugs.

None of these pricing and business practices are unique to Shkreli, who has run relatively minor organizations in the drug making world.

While we wait to see how much Newfoundland is able to extract, note that Ottawa offered two other similarly vague compensation deals to get CETA through: One on drug prices, tied to a lengthening of patent protection, and another to the dairy industry as protection against an increase in duty - free European cheese.

For instance, legislators like Sens. Elizabeth Warren of Massachusetts, Bernie Sanders of Vermont, and Jeff Merkley of Oregon recently warned that Cures amounts to a big pharma giveaway which will weaken regulatory standards on drugs, provide a mere pittance to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA), and do nothing to confront the rising tide of high drug priDrug Administration (FDA), and do nothing to confront the rising tide of high drug pridrug prices.

One of Martin Shkreli's former companies has emerged from Chapter 11 bankruptcy and is pledging to ditch its notorious ex-chief's price hike plans for a rare disease drug.

Valeant has been at the center of a political firestorm over prescription medication costs and pharmaceutical companies, which depend more on acquiring or licensing existing therapies (and then raising their prices) rather than fueling R&D into new drugs.

As a recent member of Valeant's board, I am committed to ensuring that this approach to drug pricing is never repeated at Valeant.»

Price, who has presented his own replacement plan, is now turning to a job of managing a massive agency that oversees the U.S. Food and Drug Administration, Medicare, Medicaid, the Children's Health Insurance Program and other programs, and will be tasked with implementing what Congress ultimately sends him, Childs said.

For instance, during a dinner with Republican senators Monday, Trump reportedly brought up selling insurance across state lines — one of the priorities for which he advocated in the campaign — and bringing down drug prices.

On the surface, Papa seems to have gotten an extraordinarily generous deal to turn around the beleaguered drug company: Not only is his salary more than twice what it was when he was CEO of Perrigo (prgo), a company nearly three times as valuable as Valeant (vrx), it's also especially good considering Valeant's stock price has fallen nearly 67 % since he took over.

CEO Joe Papa said he intended to wash Valeant's hands clean of the accounting and drug pricing scandals that have plagued it.

With its traditional insulin treatments in the firing line due to U.S. price pressure, Novo Nordisk is pinning hopes for growth on new obesity drugs and a once - weekly injection and tablet version of its semaglutide drug.